INTRODUCTION {#s1}
============

Lung cancer is the most frequently diagnosed lethal malignancies in the world. As the poor 5-year survival rate, lung cancer has become the leading cause of death among females in more developed countries and males in the whole world. As is known to all, smoking is regarded as a common risk factor of lung cancer. Global cancer statistics state that 15% of men and 53% of women with lung cancer were not caused by smoking \[[@R1]\]. Smoking rates in Chinese women are lower than some European countries, but the incidence of lung cancer in China is relatively high \[[@R2]\]. This suggested us that some other factors may be involved in lung cancer in Chinese female population.

Caveolae is a plasma membrane invagination and juxtamembrane vesicles, which play a role in the macromolecular vesicle transportand can be regarded as a kind of lipid raft. Due to the ubiquitous tissue distribution of caveolae, it has been confirmed that caveolae involved a large number of cellular functions. Caveolin-1 (CAV1) protein is a principal structural component of caveolae and found in the cytosolic surface of caveolae, which called caveolar coat protein. In mammalian cells, CAV1 protein is quite small and highly conserved which can recruit many signaling molecules to caveloae and regulate their activity \[[@R3]--[@R5]\].

CAV1 has been found to be involved in a variety of cancer-associated biological processes, including cell migration and metastasis, cell transformation, angiogenesis, multidrug resistance \[[@R6]--[@R9]\]. CAV1 is an interesting gene for cancer as it may play different roles in different types of cancer at different stages. No consistent results regarding whether CAV1 is an oncogene or tumor suppressor gene. Most studies suggest that CAV1 may play a positive role in the early stages of cancer onset. In advanced tumors, CAV1 is frequently associated with poor prognosis and drug resistance \[[@R10]\].

Single nucleotide polymorphism (SNP) is a kind of single nucleotide change widely distributed in the human genome. There is increasing evidence suggesting that SNPs may play a critical role in the genesis and development of cancer \[[@R11]--[@R14]\]. The relationship between SNPs in CAV1 and cancer risk has not been extensively studied. In the present study, we performed a case-control study to assess the relationship between SNPs in CAV1 and the risk or survival of lung cancer in Chinese female non-smokers.

RESULTS {#s2}
=======

Basic characteristics of subjects {#s2_1}
---------------------------------

Table [1](#T1){ref-type="table"} listed the basic information of the subjects. A total of 923 subjects were included in the present study, including 468 lung cancer cases and 455 age-matched controls. All subjects were Chinese female nonsmokers, and there was no significant difference between cases and controls with regard to age (*P*=0.861). Among cases, there were 402 non-small cell lung cancer (NSCLC) and 66 small cell lung cancer (SCLC). Among the cases with NSCLC, there were 322 cases with adenocarcinoma, 66 cases with squamous cell carcinoma and 14 cases with a variety of different rare pathologies.

###### Characteristics of included subjects

  Variables                  Cases (%)     Controls (%)   *P* value
  -------------------------- ------------- -------------- -----------
  Females                    468           455            
  Mean age (years)           56.16±11.73   56.3±11.46     0.861
  Histological                                            
   Adenocarcinoma            322 (68.8%)                  
   Squamous cell carcinoma   66 (14.1%)                   
   Small cell lung cancer    66 (14.1%)                   
   Others^a^                 14 (3.0%)                    
  Stage^b^                                                
   I                         10(2.3)                      
   II                        109(24.7)                    
   III                       267(60.5)                    
   IV                        55(12.5)                     

^a^Including adenosquamous carcinoma, mixed cell carcinoma, large cell carcinoma and undifferentiated carcinoma.

^b^There are missing values.

The effect of SNP on the risk of lung cancer {#s2_2}
--------------------------------------------

First we evaluated the relationship between the two SNPs and lung cancer risk. The results were summarized in Table [2](#T2){ref-type="table"}. Genotype distributions of rs1049337 and rs926198 in control group were all in accordance with the HWE (*P*\>0.05). Subjects carrying rs1049337 CC genotypes showed a decreased risk of lung cancer compared to the subjects carrying homozygous TT genotype (adjusted OR=0.691, 95%CI=0.482-0.990, *p*=0.044). Recessive model showed that take TT+TC genotype as reference group, CC genotype was the protective genotype of lung cancer risk (adjusted OR=0.688, 95%CI=0.510-0.929, *P*=0.015). Further analyses were carried on by allele comparison, the result indicated that compared with T allele, C allele was a protective allele of lung cancer risk (adjusted OR=0.829, 95%CI=0.691-0.995, *P*=0.045). For rs926198, taking rs926198-TT genotype as reference group, TC genotype showed a decreased risk of lung cancer (adjusted OR=0.552, 95%CI=0.367-0.830, *P*=0.004). Dominant model and additive model of rs926198 also showed statistically significant results (adjusted OR=0.557, 95%CI=0.372-0.834, *P*=0.005, adjusted OR=0.583, 95%CI=0.396-0.860, *P*=0.006, respectively).

###### Genetic polymorphisms and risk of lung cancer

                    Genotype   Lung cancer cases (%)   Controls (%)   *P* of HWE   Adjusted OR ^a^   95% CI         *P*
  ----------------- ---------- ----------------------- -------------- ------------ ----------------- -------------- -----------
  Rs1049337         TT         133 (28.4)              118(25.9)      0.061        Ref                              
                    TC         234 (50.0)              207(45.5)                   1.006             0.738,1.373    0.968
                    CC         101 (21.6)              130(28.6)                   0.691             0.482,0.990    0.044^\*^
  Dominant model                                                                   0.882             0.659,1.179    0.395
  Recessive model                                                                  0.688             0.510,0.929    0.015^\*^
  Additive model    C allele                                                       0.829             0.691,0.995    0.045^\*^
  Rs926198          TT         425(90.8)               385(84.6)      0.506        Ref                              
                    TC         42(9.0)                 69(15.2)                    0.552             0.367,0.830    0.004^\*^
                    CC         1(0.2)                  1(0.2)                      0.910             0.056,14.674   0.947
  Dominant model                                                                   0.557             0.372,0.834    0.005^\*^
  Recessive model                                                                  1.007             0.251,4.042    0.992
  Additive mode     C allele                                                       0.583             0.396,0.860    0.006^\*^

^a^Adjusted for age, ORs and 95% CIs were calculated by logistic regression. ^\*^ *P*\<0.05.

The results of stratified analysis were showed in Table [3](#T3){ref-type="table"} and [Supplementary Table 1](#SD1){ref-type="supplementary-material"}. In NSCLC cases and controls, rs926198 showed remarkable results. Compared with subjects carrying TT genotype, those whom carrying TC genotype had an adjusted OR of 0.551 (95%CI=0.359-0.846, *P*=0.006) for developing NSCLC. Dominant model and additive model of rs926198 also showed significant results.

###### Genetic polymorphisms and risk of NSCLC

                    Genotype   Controls (%)   NSCLC (%)   Adjusted OR ^a^   95% CI         *P*         Adenocarcinoma (%)   Adjusted OR ^a^   95% CI          *P*
  ----------------- ---------- -------------- ----------- ----------------- -------------- ----------- -------------------- ----------------- --------------- -----------
  Rs1049337         TT         118(25.9)      114(28.4)   Ref                                          93(28.9)             Ref                               
                    TC         207(45.5)      201(50.0)   1.008             0.984,1.011    0.962       167(51.9)            1.028             0.731,1.444     0.875
                    CC         130(28.6)      87(21.6)    0.694             0.477,1.009    0.056       62(19.3)             0.605             0.402,0.909     0.015^\*^
  Dominant model                                          0.884             0.653,1.195    0.421                            0.862             0.626,1.187     0.363
  Recessive model                                         0.692             0.506,0.946    0.021^\*^                        0.594             0.421,0.839     0.003^\*^
  Additive model    C allele                              0.830             0.686,1.003    0.054                            0.782             0.638,0.957     0.017^\*^
  Rs926198          TT         385(84.6)      365(90.8)   Ref                                          286(88.8)            Ref                               
                    TC         69(15.2)       36(9.0)     0.551             0.359,0.846    0.006^\*^   35(10.9)             0.683             0.442,1.055     0.085
                    CC         1(0.2)         1(0.2)      1.081             0.067,17.459   0.956       1(0.3)               1.317             0.0781,21.289   0.846
  Dominant model                                          0.559             0.366,0.853    0.007^\*^                        0.692             0.450,1.964     0.093
  Recessive model                                         1.176             0.073,18.967   0.909                            1.406             0.087,22.699    0.810
  Additive model    C allele                              0.588             0.392,0.882    0.010^\*^                        0.720             0.477,1.086     0.117

^a^Adjusted for age, ORs and 95% CIs were calculated by logistic regression. ^\*^ *P*\<0.05.

The results of analysis in patients with lung adenocarcinoma and controls indicated that recessive model and additive model of rs1049337 showed decreased lung adenocarcinoma risk (adjusted OR=0.594, 95%CI=0.421-0.839, *P*=0.003, adjusted OR=0.782, 95%CI=0.638-0.957, *P*=0.017, respectively). Compared with rs1049337-TT genotype, CC genotype was a protective genotype of lung adenocarcinoma (adjusted OR=0.605, 95%CI=0.402-0.909, *P*=0.015). In squamous cell carcinoma, rs926198 showed significant results, as the small sample size of squamous cell carcinoma patients, the results need to be verified in the future.

Haplotype analyses of the SNPs and lung cancer risk {#s2_3}
---------------------------------------------------

We analyzed the relationship between haplotype and lung cancer risk. The haplotypes were constructed by rs1049337 and rs926198 (Table [4](#T4){ref-type="table"}), four common haplotypes were observed. The linkage Disequilibrium (LD) plots are shown in Figure [1](#F1){ref-type="fig"}. C-C haplotye was a protective haplotype in lung cancer and NSCLC (OR=0.495, 95%CI=0.329-0.744, *P*\<0.001; OR=0.510, 95%CI=0.334-0.780, *P*=0.001; respectively). Compared with the combination of all the other haplotypes, T-T haplotype showed an increased risk of adenocarcinoma (OR=1.261, 95%CI=1.030-1.545, *P*=0.025).

###### Haplotypes and the risk of lung cancer (rs1049337-rs926198)

  Haplotype^a^   Controls (%)   Lung cancer   NSCLC                Adenocarcinoma                                                                                 
  -------------- -------------- ------------- -------------------- ---------------- ----------- -------------------- ----------- ----------- -------------------- -----------
  CC             71(7.8)        37(4.0)       0.495(0.329-0.744)   \<0.001^\*^      33(4.1)     0.510(0.334-0.780)   0.001^\*^   32(5.0)     0.627(0.408-0.963)   0.032^\*^
  CT             396(43.5)      399(42.6)     0.975(0.811-1.172)   0.787            342(42.5)   0.971(0.801-1.176)   0.762       259(40.2)   0.883(0.719-1.084)   0.234
  TC             0(\--)         7(0.7)        \--                  \--              5(0.6)      \--                  \--         5(0.7)      \--                  \--
  TT             443(48.7)      493(52.7)     1.193(0.993-1.432)   0.059            424(52.7)   1.192(0.986-1.442)   0.070       348(54.1)   1.261(1.030-1.545)   0.025^\*^

^a^Frequency of haplotypes \<3% were excluded from the final analysis. ^\*^ *P*\<0.05

![Linkage disequilibrium structure of two SNPs in CAV1\
Site1 is rs104937. Site2 is 926198. **(A)** D' linkage map of two SNPs in CAV1. **(B)** R2 linkage map of two SNPs in CAV1.](oncotarget-08-92943-g001){#F1}

The effect of SNPs on the overall survival of lung cancer {#s2_4}
---------------------------------------------------------

The results of the relationship between genetic polymorphisms and survival time were summarized in Table [5](#T5){ref-type="table"}, [Supplementary Table 2](#SD1){ref-type="supplementary-material"} and [Supplementary Figure 1](#SD1){ref-type="supplementary-material"}. We have not observed any statistically significant association between rs1049337, rs926198 and lung cancer survival time.

###### Distribution of genotypes and survival time of lung cancer patients

  SNP               Genotype   Lung cancer (%)   MST (mon)   Log-rank *P*   Adjusted HR ^a^   95% CI
  ----------------- ---------- ----------------- ----------- -------------- ----------------- -------------
  Rs1049337         TT         97(27.6)          24.5                       Ref               
                    TC         175(49.9)         24.5        0.889          1.012             0.775,1.321
                    CC         79(22.5)          25.8                       0.952             0.688,1.316
  Dominant model               254(72.4)         24.9        0.952          0.991             0.770,1.275
  Recessive model              272(77.5)         24.5        0.636          0.935             0.710,1.231
  Rs926198          TT         317(90.3)         28.3                       Ref               
                    TC+CC      34(9.7)           24.4        0.247          0.791             0.535,1.168

^a^ Adjusted for age, HRs and 95% CIs were calculated by Cox regression.

Luciferase reporter assay {#s2_5}
-------------------------

[Supplementary Table 3](#SD1){ref-type="supplementary-material"} listed the predication results of microRNAs those may bind to CAV1 mRNA around rs1049337. Considering the predication score, finally hsa-miR-612 was selected to verify its relationship with rs1049337.

The result showed that rs1049337 can affect the binding affinity of CAV1 mRNA to some microRNAs (Figure [2](#F2){ref-type="fig"}). In the A549 cell line and the H1299 cell line, we got essentially identical results. Compared with C allele, T allele had a relatively decreased relative luciferase activity. When miR-612 mimics existed in cell, T allele had a lower expression level of CAV1 compared with C allele. Compared with mimics negative control, the relative luciferase activity of vectors containing C allele and T allele was significantly decreased when miR-612 mimics existed. The results indicated that rs1049337 can affect the binding affinity of CAV1 mRNA to the corresponding microRNA, these microRNAs include miR-612.

![The results of dual luciferase reporter assay\
**(A)** Results in A549 cell line. **(B)** Results in H1299 cell line.](oncotarget-08-92943-g002){#F2}

The association of CAV1 expression level and lung cancer {#s2_6}
--------------------------------------------------------

Finally, we screened four datasets in GEO database which were suitable for our study. The results of the analysis of the relationship between CAV1 expression level and NSCLC were listed in Table [6](#T6){ref-type="table"}. We found that compared with paired normal adjacent tissue or normal lung tissue, lung cancer tissue showed a relatively low level of CAV1 mRNA (*P*\<0.001, *P*\<0.001, respectively). In three datasets (GSE19804, GSE27716 and GSE40275), we found that referring to those patients at early stage of lung cancer, the expression level of CAV1 in patients at late stage was relatively low (*P*=0.007, *P*=0.005, *P*=0.001, respectively). In GSE27716, a borderline statistical difference was found in the comparison of CAV1 mRNA levels in noninvasive lung adenocarcinoma patients and invasive lung adenocarcinoma patients (*P*=0.08).

###### The association of CAV1 expression level and lung cancer

  GEO dataset   Variable                                   N    Median^a^   *P*
  ------------- ------------------------------------------ ---- ----------- -------------
  GSE19804      Tissue                                                      
                Paired normal adjacent tissue              60   13.192      \<0.001^\*^
                NSCLC tissue                               60   10.728      
                Stage                                                       
                I                                          34   11.093      0.007^\*^
                II / III / IV                              26   10.054      
  GSE27716      Invasive                                                    
                Noninvasive lung adenocarcinoma specimen   17   8.717       0.080
                Invasive lung adenocarcinoma specimen      23   7.450       
                Stage                                                       
                Ia                                         23   8.355       0.005^\*^
                Ib / II / III                              17   7.437       
  GSE29013      Histological                                                
                Squamous cell carcinoma                    25   8.097       0.001^\*^
                Adenocarcinoma                             30   7.398       
                Stage                                                       
                I                                          24   7.852       0.519
                II / III                                   31   7.689       
                Chemotherapy                                                
                Yes                                        34   7.598       0.100
                No                                         21   7.954       
  GSE40275      Subjects                                                    
                Normal lung sample                         43   9.577       \<0.001^\*^
                NSCLC sample                               18   7.963       
                SCLC sample                                23   5.883       
                Gender                                                      
                Female                                     36   9.464       \<0.001^\*^
                Male                                       48   7.963       
                Stage                                                       
                I                                          20   7.772       0.001^\*^
                II / III                                   21   5.795       

^a^Expression level of CAV1. ^\*^ *P*\<0.05.

DISCUSSION {#s3}
==========

The role of CAV1 in cancer is oncogene or tumor suppressor gene hasn\'t been agreed yet, and the role of CAV1 in lung cancer has rarely been studied \[[@R3], [@R4], [@R7]\]. We conducted a study to explore the relationship between CAV1 gene polymorphism, expression level and lung cancer. We found that the CAV1-rs1049337, CAV1-rs926198 may affect the susceptibility of lung cancer in the Chinese female non-smokers. Further experiments revealed that compared with rs1049337-T allele, the increased relative luciferase activity was found in C allele. It was proved that the different allele of rs1049337 could affect the binding affinity of CAV1 to the corresponding microRNA. We also found that CAV1 expression may play a positive role in lung cancer.

MicroRNA is a class of single stranded noncoding RNA which is considered to regulate large number of genes at post transcriptional level. The regulatory effect of microRNA on gene expression is achieved by microRNA seed region complementary base pairing to the 3′UTR region of the target gene \[[@R15], [@R16]\]. Any nucleotide change in 3′UTR region of target gene can affect the affinity of target gene and microRNA, and further influence the expression level of target gene. Rs1049337 is located at 3′UTR region of CAV1 gene. Our study found that compared with rs1049337-T allele, C allele was a protective allele for risk of lung cancer. Further investigation demonstrated that rs1049337 can affect the binding affinity of CAV1 mRNA to the corresponding microRNAs. Finally, we found that CAV1 expression may play a positive role in lung cancer. As far as we know, there are very few studies on the relationship between rs1049337 and disease. A study on the relationship between genetic variation in CAV1 and long-term pancreas transplant function found that rs1049337 is a tag SNP of CAV1, but there\'s no significant correlation between long-term graft function, long-term pancreas function and rs1049337 was observed in donors and recipients respectively \[[@R17]\]. The MuTHER study was found that rs1049337 is an expression Quantitative Trait Loci (eQTL), and another study based on the MuTHER study revealed that rs1049337 is an eQTL with an age-by-genotype interaction effect associated to GWAS hits \[[@R18], [@R19]\]. Although we have studied the mechanism of how rs1049337 affects lung cancer, considering racial differences and the credibility of a single study, multicenter replication studies still need to be done.

Rs926198 is located at intron region of CAV1. Although we haven\'t figured out how does intron SNPs play a role in disease, a large number of genome-wide association study (GWAS) have confirmed that intron SNPs are associated with a variety of diseases in a quite robust *P* value \[[@R20]--[@R22]\]. In our study, we found that compared with rs926198-T allele, C allele was a protective allele for lung cancer risk. To the best of our knowledge, it\'s the first study to explore the relationship between rs926198 and cancer. Previous studies indicated that rs926198 is associated with metabolic syndrome, fasting insulin levels, insulin resistance, hyperinsulinemic, hypertension and systemic sclerosis \[[@R23]--[@R26]\]. After further study, Rene Baudrand et al. found that in inadipose tissues, rs926198 minor allele is associated with a lower expression level of CAV1 \[[@R24]\]. So it is necessary to further explore the mechanism of how rs926198 plays a role in the disease.

CAV1 is localized to 7q31.2, closed to D7S522 locus which is a fragile site that is frequently absent in cancer and is thought to be a suspected tumor suppressor locus \[[@R27]\]. Indeed, CAV1 is considered to play a positive role in some cancer studies, but the results of some other studies were exactly the opposite. Whether *in vitro* or in animal or in cancer patients, CAV1 is a tumor promoter gene or tumor suppressor gene that has not been consistent. Breast cancer is the most widely studied cancer with CAV1. One study found that compared with normal mammary epithelial counterparts, CAV1 showed a significant decrease in breast cancer cell, and loss of CAV1 expression was found in P53 deficient cells \[[@R28]\]. CAV1 can inhibit the growth and metastasis of breast cancer \[[@R29]\]. The molecular mechanism study revealed that in human breast cancer-associated fibroblasts, down regulated CAV1 expression play a key role in maintaining the abnormal phenotype \[[@R30], [@R31]\]. Breast cancer patients with loss CAV1 expression in stromal cells were associated with shorter survival time, increased risk of early tumor recurrence, higher recurrence rate and metastasis, higher CAV1 expression in tumor cells were associated with poor survival \[[@R32]--[@R37]\]. Other studies have suggested that CAV1 plays a negative role in breast cancer. In human breast cancer cell, CAV1 accumulates at invadopodia and its knockdown inhibits invadopodia formation \[[@R38]\]. CAV1 is thought to be a potential causative factor of trastuzumab resistance generation in breast cancer cells \[[@R39]\]. In prostate cancer cell, CAV1 is thought to promote metastatic activities, proangiogenic activities, promote tumor progression and promotes lymphangiogenesis \[[@R40]--[@R43]\]. In prostate cancer stroma, loss of CAV1 associated with reduced relapse-free survival \[[@R44]\]. The positive expression of CAV1 was more observed in high grade urothelial carcinoma and bladder cancer patients \[[@R45], [@R46]\]. In human transitional bladder cancer cell with drug resistance, the expression level of CAV1 was found to be elevated \[[@R47]\]. But one study has found that compared with normal tissue, CAV1 had a decreased expression in bladder cancer tissues \[[@R48]\]. The expression of CAV1 in colon carcinoma was up-regulated or down-regulated, the results of different studies have been quite different \[[@R49]--[@R51]\]. In Apc (min/+) mice with deficiency of CAV1, a promoted colorectal tumorigenesis was observed \[[@R52]\]. A meta analysis showed that overexpression of CAV1 was associated with a better overall survival in gastric cancer patients \[[@R53]\].

In CAV1 null (CAV-1 -/-) mouse model, hypercellularity with thickened alveolar septa was observed in lung parenchyma, disorganize and multilayer was observed in alveolar wall \[[@R54], [@R55]\]. In lung cancer cell lines, there is controversy about whether CAV1 is expressed. Compared with lung epithelial cell, one study showed that the expression of CAV1 was reduced in lung adenocarcinoma cell lines \[[@R56]\]. In another study, CAV1 was found to be reduced in small cell lung cancer cell lines, but in 76% of NSCLC cell lines, it is still expressed \[[@R57]\]. In lung cancer patients, compared with the adjacent tissues or normal lung tissue, the expression of CAV1 was down-regulated in cancer tissues \[[@R58]--[@R62]\]. But CAV1 was more frequently expressed in NSCLC patients those with drug resistance and poor prognosis \[[@R60], [@R63]--[@R65]\]. In our study, CAV1 may be considered to play a positive role in the genesis and development of lung cancer. Further study on the relationship between CAV1 and cancer is urgently needed

MATERIALS AND METHODS {#s4}
=====================

Study subject {#s4_1}
-------------

This study is approved by the ethics committee of China Medical University. Each participant signed an informed consent before participating in the study. All of the participants were unrelated Chinese Han population and non-smoking women. Patients with lung cancer were recruited from the First Affiliated Hospital of China Medical University and Liaoning Cancer Hospital& Institute. All of the patients were newly detected and had not received any radiotherapy or chemotherapy. Over the same period, controls were recruited from the health examination center of the same hospital and frequency-matched to cases in age.

Data collection and SNP genotyping {#s4_2}
----------------------------------

Clinical information of patients was collected from patients' medical records. By face-to-face interviews, we obtained the personal information from each subject. The data was recorded age, status of smoking, family history of cancer, etc. Subjects who had smoked less than 100 cigarettes in their lifetime were defined as non-smokers. Each subject was collected 10ml of venous blood. DNA was extracted from whole blood using standard Phenol-chloroform Method and was stored at -20°C for subsequent experiments. We carried out the follow up by telephone among the patients once every three months. SNPs were genotyped by using the Illumina 660W SNP microarray (Illumina Inc., San Diego, CA).

Cell culture and transfection {#s4_3}
-----------------------------

We purchased A549 and H1299 cell line from Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences. A549 and H1299 cell lines were cultured in RPMI-1640 medium (Biological Industries, Israel) supplemented with 10% fetal bovine serum (Biological Industries, Israel), 80U/ml penicilin and 0.08mg/ml streptomycin, followed by incubation with 5% CO~2~ at 37°C. A549 and H1299 cell lines transiently transfected using Opti-MEM (Gibco, USA) and Lipofectamine 3000 (Invitrogen, USA) according to the manufacturer\'s instructions.

Luciferase reporter assay {#s4_4}
-------------------------

In order to screen out those microRNAs that may binding to 3′UTR region of CAV1 mRNA around rs1049337, we adopted 4 database for microRNA predication, including MirSNP \[[@R66]\], miRNASNP \[[@R67]\], PolymiRTS Database 3.0 \[[@R68]\], SNPinfo web server \[[@R69]\].

MicroRNA mimics were purchased from GenePharma (GenePharma, China). A 602-bp fragment of CAV1 3′UTR containing rs1049337-C or rs1049337-T were amplified and cloned in GV272 vector (GeneChem, China). All reporter plasmid were verified by direct sequencing. Cell were cultured in 24-well plates, transient transfection was performed at the logarithmic phase. 48 hours after transfection, the firefly luciferase and renilla luciferase were quantified by Dual-Luciferase Reporter Assay System (Promega, USA). We performed three independent experiments and each was done in triplicate.

The association of CAV1 expression level and lung cancer {#s4_5}
--------------------------------------------------------

In order to evaluate whether the expression level of CAV1 can affect the progression and prognosis of lung cancer patients, we systematically searched the GEO database to obtain the NSCLC gene expression profile datasets with prognostic information \[[@R70], [@R71]\]. Data extraction were using GEO2R web tool in GEO database. If there are multiple probes corresponding to the same gene, the average value of these probes was calculated as the expression level of the gene.

Statistical analysis {#s4_6}
--------------------

Student\'s *t*-test (for continuous variable) and chi-squared test (for categorical variables) were used to measure the difference between two groups in the distribution of demographic characteristics. Comparison of continuous variables between three or more groups were used one-way analysis of variance (ANOVA). In control group, the Pearson chi-squared test was adopted to determine whether the genotype frequencies follow Hardy-Weinberg equilibrium (HWE). Unconditional logistic regression model was applied to calculate the odds ratios (ORs) and their 95% confidence intervals (CIs) to evaluate the relationship between SNPs and lung cancer risk with adjustment for age. The haplotypes frequency estimation and the analysis of association between haplotypes and lung cancer risk were using SHEsis online web-server \[[@R72], [@R73]\]. Statistical analyses were carried out using SPSS 22.0 software (IBM, USA). All *p* value were two sided and *p*\<0.05 was considered statistically significant.

SUPPLEMENTARY MATERIALS FIGURE AND TABLES {#s5}
=========================================
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